Literature DB >> 20406251

Acute administration of benzodiazepines as part of treatment strategies for epilepsy.

Peter Wolf1.   

Abstract

Ad-hoc administration of benzodiazepines (BZD) is well established in status epilepticus, but intermittent BZD use in the treatment of chronic epilepsy is little known beyond catamenial epilepsy. We aim to assess the use of acute drug administration (ADA) in the treatment of 24 patients with epilepsy (9 idiopathic generalized, 14 focal symptomatic/cryptogenic, 1 migraine-epilepsy) receiving ADA for (1) prevention of generalized tonic-clonic seizures (GTCS) after minor seizures, (2) prevention of seizures at perceived risk, (3) prevention of seizure clusters. Standard ADA was 10 mg oral clobazam (CLB); one patient received 10 mg rectal diazepam. Concomitant antiepileptic drugs (AED) remained unchanged whenever possible. Ten patients used ADA always correctly, 7 mostly, 7 sporadically or not. Outcome considering seizure control was positive in 44% of all patients (59% of those who actually used ADA): 5 patients seizure free, 1 free of disabling seizures, 4 with >50% reduction in seizure frequency. Eleven had minor or no improvement, 3 patients could not be rated. Thirteen (of 19 possible) patients attempted prevention of seizures or clusters, 10 with full or >50% success (52.6 resp. 76.9%). Prevention of clusters sometimes required higher or repetitive CLB dosing. Self rating of patients who did use ADA was positive or very positive in 88.2%. Retention rate was 66.7% of all patients, and 88.2% of those using ADA. The best results were obtained in idiopathic generalized epilepsy (IGE) patients with seizures habitually triggered by typical factors (sleep deprival, alcohol) but also some others were successful. The only adverse effect was gait ataxia in a multiple-handicapped patient. ADA is an elegant and often successful but underused treatment option for selected patient groups where it can make the difference between becoming seizure free or not. Depending on the individual case it can be applied as monotherapy or in combination with a basis AED. A controlled investigation should follow.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20406251      PMCID: PMC6493823          DOI: 10.1111/j.1755-5949.2010.00139.x

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  6 in total

Review 1.  Drug-induced cerebellar ataxia: a systematic review.

Authors:  J van Gaalen; F G Kerstens; R P P W M Maas; L Härmark; B P C van de Warrenburg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

Review 2.  Rescue therapies for seizures.

Authors:  Valeriya S Poukas; John R Pollard; Christopher Todd Anderson
Journal:  Curr Neurol Neurosci Rep       Date:  2011-08       Impact factor: 5.081

3.  Use of Interval Therapy with Benzodiazepines to Prevent Seizure Recurrence in Stressful Situations.

Authors:  Roy G Beran
Journal:  Brain Sci       Date:  2022-04-19

Review 4.  Specialist management of routine dental procedures in adults with refractory epilepsy.

Authors:  N Ransford; I Soryal; D McCorry; J W Sander; F Duncan; N Huggins
Journal:  Br Dent J       Date:  2014-04       Impact factor: 1.626

5.  Effect of levetiracetam drug on antioxidant and liver enzymes in epileptic patients: case-control study.

Authors:  Atena Mahdavi; Amirmansour Alavi Naeini; Mohammadreza Najafi; Mohammadreza Maracy; Mohammadreza Aghaye Ghazvini
Journal:  Afr Health Sci       Date:  2020-06       Impact factor: 0.927

Review 6.  Rational Polytherapy with Antiepileptic Drugs.

Authors:  Jong Woo Lee; Barbara Dworetzky
Journal:  Pharmaceuticals (Basel)       Date:  2010-07-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.